Trial
NCT02122172
Afatinib in Advanced Refractory Urothelial Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Chicago
Collaborators
National Cancer Institute (NCI)
Condition
Distal Urethral Cancer
Intervention
afatinib dimaleate
Why stopped
Unable to meet accrual goal after several years
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-04-25